Taysha Gene Therapies, Inc. TSHA Payments to Acquire in Process Research and Development
Payments to Acquire in Process Research and Development at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s payments to acquire in process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s payments to acquire in process research and development?
- Taysha Gene Therapies, Inc. (TSHA) reported payments to acquire in process research and development of $3M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s payments to acquire in process research and development changed year-over-year?
- Taysha Gene Therapies, Inc.'s payments to acquire in process research and development increased by 693.7% year-over-year, from $378K to $3M.